Novo Nordisk's Paediatric Win Fails to Move the Needle as Investors Await London Reckoning
Published on 09/07/2026 at 21:20 | Editorial boerse-global.de
The clinical news coming out of Novo Nordisk's pipeline keeps getting better. The share price, however, remains stubbornly indifferent.
That disconnect was on full display this week when the Danish drugmaker unveiled Phase 3 results from its STEP-Young study. Among children aged six to under twelve treated with once-weekly semaglutide, 40.4 percent were no longer classified as obese after 68 weeks, compared with zero percent in the placebo arm. The safety profile matched what had already been observed in adult and adolescent trials, with no new risks emerging.
The market's response was a shrug. Shares slipped 0.2 percent to EUR 39.99 on the day, extending a stretch of listlessness that has defined the stock for months. The equity now sits 27 percent below its 52-week high of EUR 54.86, touched back in January, with a year-to-date decline of 9.2 percent and a 14 percent drop over twelve months.
The pattern is becoming familiar: pipeline breakthroughs no longer move the dial, because the concerns weighing on investors are not scientific but commercial.
A Sell Rating, A Buyback, and a Split on Wall Street
The scepticism has crystallised into a clear divide among analysts. Deutsche Bank downgraded the stock to Sell on August 27, trimming its price target to DKK 265, citing softening growth prospects for 2027, late-stage pipeline setbacks — most notably the failure of Ziltivekimab — and the looming threat of patent expiry later this decade. The bank reaffirmed that negative stance on September 2.
Citi has struck a similar chord, maintaining its Sell rating with the same DKK 265 target on September 2 while pointing specifically to weakening trends in new-patient starts across the entire obesity portfolio. That metric — the number of patients initiating treatment — has become the single most-watched figure for determining whether the current share price weakness represents an overreaction or a justified reassessment of growth velocity.
JPMorgan offers the counterweight. On August 25, the bank lifted its price target from DKK 250 to DKK 275 while keeping a Neutral stance, raising its 2026 revenue forecast by 5 percent on expectations of more limited generic erosion for Ozempic and favourable US price adjustments.
Two houses, two opposing conclusions. The bears fixate on the patent cliff and a disappointed cardiovascular pipeline. The more constructive camp sees pricing power at the existing blockbusters as far from broken. Both readings carry weight, and the share price reflects the standoff: the 50-day moving average sits at EUR 41.60 and the 200-day average at EUR 40.15, with the stock hovering just beneath the latter without committing to a direction.
Management, for its part, continues to signal confidence through action. The buyback programme has been running unabated — as of September 4, Novo Nordisk had repurchased 32,034,179 B-shares since early February at an average price of DKK 281.63, for a total outlay of roughly DKK 9 billion. The purchases have yet to provide visible support to the share price, but they underscore that the board sees value where the market currently does not.
China's Oral Wegovy Filing Adds Another Open Variable
While the paediatric data captured the clinical spotlight, a separate regulatory development may carry greater weight for the stock's medium-term trajectory. China's drug regulator formally accepted the marketing application for the oral version of Wegovy in late August.
Just as Novo Nordisk must navigate complex regulatory reviews, UK employers face their own compliance scrutiny — particularly around workplace risk assessments. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay on the right side of H&S law. Download the free Risk Assessment Toolkit
Novo Nordisk has offered no timeline for a decision, stating only that it will respect the standard review process. For investors, that leaves the Chinese market as an unresolved variable rather than a confirmed growth driver. A green light would open an enormous patient pool without any fixed date attached; a delay or rejection would remove a catalyst on which the market has partially begun to speculate.
The German launch of the Wegovy tablet last Friday has done little to shift sentiment either, with the stock down 0.6 percent since that introduction.
September 21 Looms as the Defining Moment
All of these threads converge on a single date: September 21, when Novo Nordisk hosts its capital markets day in London. Management is expected to lay out strategy, pipeline priorities and operational outlook — precisely the subjects over which Deutsche Bank and JPMorgan currently part ways.
The bull case rests on the possibility that recent new-patient trends prove to be seasonal distortions or artefacts of wholesaler inventory adjustments rather than structural erosion. If the company can demonstrate stabilising prescription growth in the US and Europe, the currently negative analyst positioning could unwind quickly. A clearer China strategy for oral Wegovy would add further upside optionality.
The bear case warns that the softening Citi identified may be structural — Eli Lilly's competitive pressure pulling away market share, or pricing and reimbursement debates permanently dampening new prescriptions. Should the capital markets day fail to deliver a convincing answer on the new-patient question, the stock's downward drift could well resume.
The technical picture offers little comfort in the interim. Trading marginally below the 200-day average suggests fragile medium-term momentum, with the shares likely to remain rangebound until fresh information arrives.
The STEP-Young results are genuinely encouraging for the long-term substance of the semaglutide franchise, extending its reach into an age group where few competitors currently operate. But they do nothing to resolve the near-term uncertainty around growth velocity and competitive intensity. Until the London event provides greater clarity on life after the patent cliff, Novo Nordisk's equity appears destined to remain trapped in its narrow trading band — clinical triumphs notwithstanding.
